None listed
Conditions
Brief summary
This study will review the intervention of administration of oral propranolol tablets to patients with HHT (Hereditary Haemorrhagic Telangiectasia) . Patients will be monitored to see if Propranolol helps reduce epistaxis (nosebleeds) . The most common symptom of HHT is having recurrent, spontaneous nosebleeds. Propranolol has been used for a similar purpose in another group of patients with good effect. If it should work it would be a very simple and cost effective way to reduce patient symptoms and approve quality of life for these patients..
Interventions
The medication Propranolol oral tablets will be prescribed for the patients at a dose of 40mg once daily for 6 months. Adherence will be monitored using a 'drug dispensation and accountability log". This will record exactly what is dispensed to the patient and on return of the propranolol bottle it will be recorded how many tablets were actually taken by the patient to measure compliance.
Sponsors
Royal brisbane and Women's Hospital
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Participants with a diagnosis of HHT according to curacao criteria score of >4 Participants with an Epistaxis severity score of >4 despite conventional treatment
Exclusion criteria
Absolute contraindication to Propranolol e.g. Bradycardia Pregnancy or breast feeding Planned surgical intervention for epistaxis control Deemed by cardiologist as unsuitable for taking Propranolol medication
Outcome results
None listed